Advantage to dose-dense Taxol?
Meet the Experts
Jennifer Griggs, M.D., M.P.H. is a medical oncologist specializing in the treatment of breast cancer, with a a special interest in cancer survivorship, patient-physician communication, and quality of care for women with breast cancer.
Marisa Weiss, M.D. is a radiation oncologist specializing in breast cancer and the founder, president, and guiding force behind Breastcancer.org.
Question from Sprph: Is there any advantage to 12 weeks of Taxol vs. 4 weeks of dose-dense Taxol?
- Answers —Jennifer Griggs, M.D., M.P.H.: There are studies investigating the best way of giving Taxol and the related drug Taxotere. For now, we know that these drugs are very important in women at high risk of recurrent disease.
On the other hand, for many patients, these drugs are not necessary. We are always trying to improve treatment of breast cancer, and it seems as though the progress is occurring at a faster and faster pace. Again, clinical trials are underway to answer your question. - Marisa Weiss, M.D., president and founder: Stay tuned!
On Wednesday, February 18, 2004, our Ask-the-Expert Online Conference was called Chemotherapy Updates. Jennifer Griggs, M.D., M.P.H. and Marisa Weiss, M.D. answered your questions about advances in chemotherapy treatment: different types of drugs and regimens, how to reduce or eliminate unpleasant side effects, and more.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2008. All rights reserved.